logo
Plus   Neg
Share
Email

Sorrento To Explore Its Agents In Combination With ViralClear's Merimepodib Against COVID-19

ViralClear Pharmaceuticals, Inc. (BSGM) and Sorrento Therapeutics, Inc. (SRNE) have entered into an agreement to explore the synergistic potential of small molecules and antibodies combination therapies against COVID-19. ViralClear will contribute its oral antiviral Merimepodib which is currently in a phase 2 trial in combination with remdesivir to treat COVID-19. The agreement will allow for testing of merimepodib with neutralizing antibodies in the Golden Syrian hamster model of COVID-19.

The companies said, pending the outcome of these studies, the results might be presented to the FDA to support the initiation of a human clinical trial of the drug combination.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Telecom giant AT&T, Inc. reported Thursday a 24 percent decline in profit for the third quarter, primarily hurt by lower revenues across all its operating segments amid the impact from COVID-19 pandemic. Adjusted earnings for the quarter met analysts' expectations, while quarterly revenues topped their estimates. A Brazilian volunteer, who participated in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University, has died, Brazilian health authority Anvisa said. Oxford university reportedly confirmed the plan to continue the trial after careful assessment that there have been no concerns about safety of the clinical trial. NASA's Osiris-Rex robotic spacecraft briefly touched down on near-Earth asteroid Bennu's surface on Tuesday to collect rock and dust samples that will be brought back to Earth in 2023. Bennu is currently more than 200 million miles, or 321 million kilometres, from Earth. Osiris-Rex launched from Cape Canaveral Air Force Station in Florida in September 2016.
RELATED NEWS
Follow RTT